This will be a single-center, open-label, crossover, single modified-release-dose, study in male subjects to evaluate the pharmacokinetics of prototype modified-release formulations compared to the reference immediate-release apremilast formulation. Subjects will be randomly assigned to a treatment sequence. A total of up to 8 test MR formulations may be evaluated.